Purpose of review A successful human immunodeficiency virus-type 1 (HIV-1) vaccine will require immunogens that induce protective immune responses. However, recent studies suggest that the response to HIV-1 and perhaps other viruses may be altered by immune system exposure to intestinal microbiota-antigens. This review will discuss select aspects of these studies.
INTRODUCTION
Both B cell receptor (BCR) and T cell receptor (TCR) diversity contributes to the development of an effective humoral immune response that can recognize pathogens and environmental antigens [1] . Many B cells responding to pathogens are polyreactive, and thus are capable of responding to multiple antigens [2] . In this regard, naïve B cell subsets can be stimulated with environmental antigens and become primed for responding to pathogens and vaccine-immunogens with shared properties, including sequence and structural motifs [2] [3] [4] . The notion that environmental antigens can prime naïve B cell subsets to respond to pathogens is important for understanding CD4 T and B cell responses to infectious diseases. Here we discuss recent findings of intestinal microbiota cross-reactivity with viruses, focusing on HIV-type 1 (HIV-1) envelope (Env) cross-reactivity with bacterial intestinal microbiota.
CROSS-REACTIVE T CELL RESPONSES IN VIRAL INFECTIONS
For generating a T cell response, T cells must be present in sufficient numbers to recognize a specific antigen, but given the remarkable number of environmental antigens, the TCR repertoire must be able to recognize a vast array of peptides in the context of major histocompatibility complex (MHC) class I or class II [5] . The ability of T cells to bind multiple ligands may be conferred by cross-reactivity with environmental antigens of similarity in epitopes recognized by T cells or the flexibility of TCR recognizing different epitopes presented by the same MHC [6, 7] . Intestinal microbiome proteins are candidate environmental antigens with sequence and structural similarities to viruses that may be able to stimulate naïve T cells [7] .
Antigen-specific CD4 T helper cells, particularly T follicular helper cells, are required for optimal B cell affinity maturation and class switching [8] . Two studies have shown the existence of memory CD4 T cells that cross-reacted with HIV-1 and intestinal microbiota peptides in HIV-1-uninfected individuals [9, 10] . Using a human leukocyte antigen (HLA)-restricted, peptide-MHC tetramer enrichment technique, Su et al. [10] characterized the CD4 T cell repertoire in 26 healthy adults and found T cells that reacted with tetramers derived from HIV-1, cytomegalovirus or herpes simplex virus epitopes. Reactive T cells had surface markers and gene expression profiles of memory T cells and showed evidence of clonal expansion. Su et al. [10] demonstrated that one mechanism for accruing virus-specific CD4 T cells was naïve CD4 T cell cross-reactivity with environmental antigens, including microbiota antigens. Specifically, peptides derived from intestinal commensal bacteria Ruminococcus flavefaciens, Lachanospiraceae bacterium and Bifidobacterium bifidum had sequence homology with HIV-1 peptides and were found to cross-react with CD4 T cells [10] . Similarly, influenza-reactive T cells from two individuals vaccinated with an influenza vaccine responded to an HA 391-410 peptide sequence and could be activated by peptides from a human skin bacterium Finegoldia magna [10] . Similarly, Campion et al. [9] used an HLA-unbiased T cell library technique to characterize the naïve and memory T cell repertoires of seven healthy HIV-1 seronegative individuals and found clonally expanded naïve and memory CD4 T cells that reacted with HIV-1 peptides. The HIV-1 peptides that cross-reacted with naïve and memory CD4 T cells from HIV-1-negative individuals had epitope-length matches with microbial sequences of human microbiome proteins, suggesting that microbial proteins could have been responsible for T cell priming [9] . Therefore, using two independent approaches, both Su et al. and Campion et al. found naïve and memory CD4 T cells that cross-reacted with virus and intestinal microbiota-antigens and provided evidence that virus-reactive T cells may be induced by cross-reactivity with environmental antigens, including commensal microbial antigens. Thus, CD4 T cell antiviral repertoires may be shaped by microbial antigens and can influence the immune response to HIV-1 vaccines.
Preexisting naïve CD8 T cells that can recognize viral antigens have also been described. Schmidt et al. [11] found naïve CD8 T cells that cross-reacted with hepatitis C virus (HCV)-epitopes in seven HCV-uninfected individuals. Significantly, the HCV epitope that most commonly reacted with naïve precursor CD8 T cells in the uninfected individuals was the most frequently targeted epitope in an independent cohort of 26 HCV-infected individuals, suggesting that immunodominance in HCV infection was linked to precursor frequency of CD8 T cells cross-reactive with HCV-specific epitopes [11] .
CROSS-REACTIVE B CELL RESPONSES IN VIRAL INFECTIONS
Humans have a diverse B cell repertoire capable of generating antibodies that can mediate immune effector functions against viruses and virus-infected cells [1] . High-affinity anti-pathogen antibodies are generally monospecific as host tolerance mechanisms, including clonal deletion, anergy and receptor editing, normally restrict the maturation of high-affinity autoreactive B cells during B cell development [12, 13] . However, 20% of mature naïve B cells are low-affinity self-reactive or polyreactive, and provide breadth of response to the BCR repertoire [13] . Interestingly, HIV-1 Env-reactive antibodies, including broadly neutralizing antibodies (bnAbs), are frequently polyreactive [14, 15] and have been suggested to be derived from a polyreactive pool of B cells such as marginal zone B cells and to be controlled by immune tolerance mechanisms [14, [16] [17] [18] . Polyreactivity may be beneficial for HIV-1 Env-reactive antibodies, as neutralizing antibody epitopes on glycosylated HIV-1 Envs mutate extensively during viral evolution, are shielded by glycans, and each virion contains 7-10 functional viral spikes [15, 19] . Polyreactivity of HIV-1 Envreactive antibodies may be conferred by high levels
KEY POINTS
The microbiome can influence immune responses to infections.
Cross-reactivity of naïve and memory CD4 T and B cells occurs with intestinal microbiota antigens.
The microbiome can modulate antibody responses to HIV-1 Env vaccines.
Modification of the microbiome and HIV-1 Env-intestinal microbiota cross-reactive epitopes may enhance HIV-1 Env vaccine responses.
The microbiome in HIV of somatic mutations [15] , thus suggesting that polyreactive B cells may be positively selected in response to HIV-1 infection.
In acute HIV-1 infection (AHI), the initial humoral immune response consists of plasma IgM and IgG antibodies that target the gp41 region of HIV-1 Env and are non-neutralizing and ineffective at controlling viremia [20] . It was interesting to note that in AHI, both IgM and IgG responses arise at the same time, implying a mixture of IgM and IgG BCRexpressing responding B cells in AHI [20] . Two subsequent studies addressed the origin of predominant gp41-reactive antibodies during AHI [3, 4] . Ninetyone percent (61/67) of the Env-reactive antibodies isolated from plasma cells of the five AHI patients were gp41-reactive, consistent with immunodominance of gp41-reactive plasma antibodies [3, 20] . Moreover, plasma cell-derived gp41-reactive antibodies from AHI were highly mutated and thus led to the hypothesis that they originated from a pool of preexisting mutated B cells that cross-reacted with HIV-1 Env gp41 [3] . Liao et al. [3] went on to isolate gp41-reactive antibodies from plasma cells in peripheral blood of two uninfected individuals and demonstrated that the gp41-reactive antibodies from uninfected and AHI patients were indeed cross-reactive with intestinal microbiota-antigens. Trama et al. [4] studied the plasma cell and memory B cell repertoires of the terminal ileum in early and chronically HIV-1-infected individuals. Mutated gp41-reactive antibodies that cross-reacted with intestinal microbiota-antigens were also dominant in terminal ileum of six early-HIV-1-infected and three HIV-1-uninfected individuals [4] . Thus, both of these studies suggested that the initial gp41-reactive antibody response observed in AHI were derived from a pool of preexisting intestinal microbiotacross-reactive B cells [3, 4] . That gp41-intestinal microbiota cross-reactive antibodies were classswitched and mutated, supported the hypothesis that these antibodies were derived from a pool of preexisting B cells primed by intestinal microbiotaantigens.
Recent studies have assessed how changes in the microbiome following HIV-1 infection may impact disease progression toward AIDS. In a cohort of HIV-1-infected Ugandan individuals, postinfection fecal virome DNA was characterized using next generation sequencing, and the bacterial microbiome was characterized using 16S rRNA gene amplification [21 & ]. Analysis in HIV-1-infected Ugandans revealed alterations of virome and bacterial microbiome that were associated with low peripheral CD4 T cell counts. HIV-1-infected Ugandan patients with CD4 T cell count less than 200 had significantly less bacterial phylogenetic diversity compared with infected patients with CD4 T cell count more than 200 and HIV-1-uninfected patients [21 & ]. In a cohort of rhesus macaques that received an Ad26 prime, Env protein vaccine prior to simian immunodeficiency virus (SIV) challenge, the overall bacterial communities remained relatively stable after SIV infection independent of vaccine-mediated protection, but the fecal samples of unprotected animals had a higher frequency of gastrointestinal adeno-associated viruses and picornaviruses compared with the fecal samples from vaccine-protected animals [22 & ]. Moreover, detection of adenovirus sequences in SIVinfected macaques was associated with macaque death due to AIDS-related complications, suggesting a possible emergence of pathogens during lentivirus infections [22 & ]. Thus, these studies demonstrated that gut viruses and bacteria are impacted by lentivirus infection, and SIV vaccination may prevent overgrowth of pathogens that promote disease progression [21
Microbiota regulation of B cell responses has also been reported to impact antibody responses to influenza. Germ-free mice immunized with trivalent inactivated influenza vaccine (TIV) had impaired TIV-specific antibody responses that were restored upon recolonization of germ-free mice with strains of Escherichia coli microbiota antigen, thus demonstrating a role for gut microbiota in response to influenza vaccines [23] .
CROSS-REACTIVE B CELL RESPONSES IN HIV-1 ENVELOPE VACCINATION
A National Institute of Health Vaccine Research Center (VRC) DNA prime, recombinant adenovirus type 5 (rAd5) boost vaccine (VRC vaccine) that was studied in an HIV Vaccine Trials Network (HVTN) phase IIb human vaccine efficacy trial (HVTN 505) in adult participants showed futility for protection against HIV-1 acquisition [24] . This VRC vaccine was also studied in HVTN phase 1b (HVTN 082) and phase 2a (HVTN 204) human clinical trials [25,26 & ]. The dominant plasma and memory B cell-derived antibodies induced by this VRC vaccine were neither neutralizing nor mediated FcRdependent anti-HIV-1 activities [24, 26 & ]. The dominant blood-derived vaccine-induced antibody responses targeted the gp41 region of Env, gp41-reactive antibodies cross-reacted with intestinal microbiota-antigens, and gp41-reactive antibodies originated from B cells cross-reactive with both intestinal microbiota and HIV-1 Env that were present prior to vaccination [26 prime , Modified Vaccina Ankara boost with HIV-1 Env gp140 [27] .
Infants live in a relatively sterile environment prior to birth [28] , but neonate B cell repertoires may be imprinted soon after birth by microbiota antigens [29, 30] . Thus, one hypothesis for induction of HIV-1 protective antibodies is to vaccinate infants early in life. The immune cells of neonates and adults have phenotypic and functional differences [31] , but infants can respond robustly to some vaccines [32] . We recently immunized neonate macaques with the VRC DNA prime, rAd5 boost vaccine at 2-6 days after birth and found that vaccine-induced memory B cell-derived antibodies were predominantly gp41-reactive, and 16S rRNA-derived intestinal microbiota taxa profile was similar for neonate and adult macaques immunized with the same VRC vaccine [33 & ]. These data confirmed that the imprinting of the B cell repertoire occurs soon after birth. A recent review highlighted studies that suggested that the infant microbiome can in some cases be seeded in utero [34] . In addition, neonate B cells have been shown to express CD5 and CD1c, markers of marginal zone B cells [35, 36] , and marginal zone B cells have lowaffinity IgM, autoreactive and polyreactive BCRs [37, 38] . As HIV-1 bnAbs are frequently autoreactive and subjected to immune tolerance controls during B cell lineage development in adults [14, 18] , the polyreactive nature of infant B cells could be exploited for bnAb induction via HIV-1 vaccination. Indeed, human infants that are HIV-1 infected have a higher frequency of bnAbs and generate them sooner than HIV-1-infected adults [39,40 & ]. HIV-1-induced immune dysfunction with disrupted immune tolerance has been associated with bnAb induction [41 & ]. Thus, one hypothesis to explain these observations in infants is that infant immune systems have possibly less stringent immune tolerance controls or respond to HIV-1 infection with more HIV-1-induced immune dysregulation.
Macaques are used as an animal model to study human HIV-1 infections and for testing candidate HIV-1 vaccines [42] . Thus, evaluating gp41 immunodominance induced by HIV-1 Env gp140 in macaques is important for the HIV-1 vaccine field. Han et al. [33 & ] recently showed that, as in humans, the VRC DNA prime, rAd5 boost vaccine induced a dominant gp41-reactive, memory B cell response in both neonate and adult macaques. In this study, Han et al. also showed intestinal microbiota-cross-reactivity of the VRC vaccine-induced gp41-reactive antibodies. Thus, neonatal non-human primates may be a model to define immunoregulatory controls of bnAb induction in HIV-1 infection, and to elucidate roles the microbiome might have in imprinting the B cell repertoire to respond to pathogens.
HIV-1 ENVELOPE AND INTESTINAL MICROBIOTA CROSS-REACTIVE EPITOPES
Many cross-reactive epitopes between HIV-1 proteins and human proteins have been described [43, 44] Identifying intestinal microbiotaantigens and epitopes for Env-intestinal microbiota cross-reactivity will provide a toolbox of intestinal microbiota proteins that can be used to evaluate the intestinal microbiota-cross-reactivity of candidate HIV-1 Env vaccine immunogens. The new generation of stabilized trimers (SOSIPs) has been designed to present only bnAb epitopes that can be recognized by the immune system during vaccination [46] [47] [48] [49] . The membrane proximal external region targeted by gp41-reactive bnAbs was not included in the SOSIP trimers, but a portion of the gp41 ectodomain region remained at the base of these proteins. Although most studies have found SOSIP trimers to induce primarily autologous tier 2 nAbs [50] [51] [52] , a recent study in mice has shown that BG505 SOSIP.664 trimers induced nonneutralizing antibodies that targeted the base of the SOSIP [53] . It will be key to determine if the new generation of HIV-1 Env immunogens induce gp41-dominant responses in non-human primates or in humans.
CONCLUSION
The microbiome can shape the repertoire of immune cells to respond to viruses, and influence the response to vaccine immunogens (Fig. 1) . Analysis of individuals vaccinated with HIV-1 Envimmunogens has demonstrated that intestinal microbiota-antigen cross-reactivity with HIV-1 Env can possibly divert HIV-1 Env vaccine-induced antibody responses away from protective immunity. Here we have reviewed evidence for three hypotheses: the microbiome can influence the specificity of B and CD4 T cell responses to infections; the microbiome can modulate the response to HIV-1 Env immunization; and modification of the microbiome may enhance vaccine responses. 
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